CT
MDGL icon

Cambridge Trust’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cambridge Trust’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$17.4K Hold
65
– – ﹤0.01% 537
2023
Q4 		$15K Hold
65
– – ﹤0.01% 536
2023
Q3 		$9.49K Hold
65
– – ﹤0.01% 584
2023
Q2 		$15K Hold
65
– – ﹤0.01% 555
2023
Q1 		$15.7K Hold
65
– – ﹤0.01% 582
2022
Q4 		$19K Hold
65
– – ﹤0.01% 566
2022
Q3 		$4K Hold
65
– – ﹤0.01% 729
2022
Q2 		$5K Hold
65
– – ﹤0.01% 743
2022
Q1 		$6K Hold
65
– – ﹤0.01% 798
2021
Q4 		$6K Buy
+65
New +$5.34K ﹤0.01% 881

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Cambridge Trust's MDGL Position: Q1 2024 in Review

Cambridge Trust held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2024 at 65 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Cambridge Trust first reported a position in MDGL in Q4 2021 and has held it in 10 quarters since. The position peaked at $19K in Q4 2022. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Cambridge Trust held 65 shares of Madrigal Pharmaceuticals worth $17.4K as of Q1 2024.
  • Cambridge Trust left its Madrigal Pharmaceuticals share count unchanged in Q1 2024.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #537 holding.
  • Cambridge Trust first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
  • Cambridge Trust's Madrigal Pharmaceuticals position peaked at $19K in Q4 2022.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.